Computer model may help tailor blood pressure meds for liver patients

NCT ID NCT07397481

Completed Disease control Sponsor: Kafrelsheikh University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a computer program (Simcyp) could predict the right doses of two blood pressure drugs, nebivolol and carvedilol, for people with liver cirrhosis and high blood pressure. Forty patients were randomly assigned to one of the two drugs and monitored for three months. Researchers measured blood pressure, liver blood flow, and side effects to see if the computer-guided doses worked well in real life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nebivolol and carvedilol (blood pressure medications)
What this could lead to: If successful, this approach could help doctors choose safer, more effective doses of blood pressure drugs for patients with liver cirrhosis.
What could go wrong: This is a small, early pilot study with only 40 patients, so results may not apply to everyone. The computer predictions need more testing before routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver essential hypertension hypertensive disorder portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARTERIAL HYPERTENSION LIVER CIRRHOSIS

Contacts and locations

Locations

Kafrelsheikh University

Cairo, Egypt, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.